Investors Buy Large Volume of Boston Scientific Put Options (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) was the recipient of some unusual options trading on Tuesday. Investors purchased 37,743 put options on the stock. This is an increase of 28% compared to the average daily volume of 29,562 put options.

Boston Scientific Price Performance

NYSE BSX traded up $0.76 on Tuesday, reaching $45.09. 2,779,931 shares of the company’s stock traded hands, compared to its average volume of 17,646,100. Boston Scientific has a 12 month low of $44.05 and a 12 month high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The stock has a 50-day simple moving average of $54.37 and a 200 day simple moving average of $72.44. The stock has a market cap of $67.01 billion, a PE ratio of 18.88, a P/E/G ratio of 0.87 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same period in the previous year, the business posted $0.75 EPS. The business’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts predict that Boston Scientific will post 3.36 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has approved a share repurchase program on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BSX shares. Oppenheimer set a $90.00 price objective on shares of Boston Scientific in a research report on Thursday, April 23rd. Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings cut shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Daiwa Securities Group lowered shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Finally, Stifel Nicolaus set a $75.00 price objective on shares of Boston Scientific in a research report on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $85.08.

Insider Buying and Selling

In other news, Director David C. Habiger acquired 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the acquisition, the director owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Cheryl Pegus purchased 1,770 shares of the stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the transaction, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have purchased 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by insiders.

Institutional Trading of Boston Scientific

Several institutional investors have recently added to or reduced their stakes in the business. Norges Bank purchased a new position in shares of Boston Scientific in the fourth quarter worth about $2,199,395,000. Assenagon Asset Management S.A. boosted its holdings in Boston Scientific by 133.6% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock valued at $631,135,000 after acquiring an additional 5,751,760 shares during the period. Janus Henderson Group PLC grew its position in Boston Scientific by 31.0% during the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after acquiring an additional 3,907,981 shares during the last quarter. Egerton Capital UK LLP increased its stake in Boston Scientific by 223.7% in the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after purchasing an additional 3,671,548 shares during the period. Finally, Maverick Capital Ltd. purchased a new position in Boston Scientific in the 4th quarter worth approximately $280,735,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.